Yu-Yun Shao

List of Publications by Year
in descending order

122	2,195	201674	276875
papers	citations	27 h-index	41 g-index

124	124	124	3478
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Early alphaâ€fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer, 2010, 116, 4590-4596.	4.1	154
2	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of Hepatology, 2010, 53, 126-131.	3.7	124
3	High Serum Transforming Growth Factor-Î²1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib. Clinical Cancer Research, 2015, 21, 3678-3684.	7.0	76
4	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2021, 120, 1051-1060.	1.7	72
5	Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*. Molecular and Cellular Proteomics, 2015, 14, 1527-1545.	3.8	71
6	Clinical Trials in Hepatocellular Carcinoma: An Update. Liver Cancer, 2013, 2, 345-364.	7.7	58
7	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	7.7	57
8	Early alphaâ€foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver International, 2019, 39, 2184-2189.	3.9	55
9	Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. Analytica Chimica Acta, 2018, 1019, 93-102.	5.4	50
10	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. Journal of Hepatology, 2014, 60, 313-318.	3.7	47
11	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. Oncology, 2013, 85, 44-52.	1.9	46
12	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer, 2019, 8, 110-120.	7.7	46
13	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer, 2016, 16, 327.	2.6	42
14	Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Clinical Cancer Research, 2016, 22, 2555-2564.	7.0	42
15	Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy. Clinical Cancer Research, 2012, 18, 3992-3997.	7.0	41
16	Inhibition of the Wnt/Î²-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Cancer Letters, 2016, 381, 58-66.	7.2	39
17	Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?. World Journal of Gastroenterology, 2015, 21, 10336.	3.3	38
18	The Impact of Diabetes Mellitus on Prognosis of Early Breast Cancer in Asia. Oncologist, 2012, 17, 485-491.	3.7	37

#	Article	IF	Citations
19	High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. Japanese Journal of Clinical Oncology, 2017, 47, 949-953.	1.3	37
20	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. Clinical Colorectal Cancer, 2015, 14, 177-184.e4.	2.3	36
21	Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?. Liver Cancer, 2013, 2, 93-107.	7.7	35
22	Î²-Catenin<i> (CTNNB1)</i> Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma. Oncology, 2014, 87, 159-166.	1.9	35
23	Increasing Incidence of Brain Metastasis in Patients with Advanced Hepatocellular Carcinoma in the Era of Antiangiogenic Targeted Therapy. Oncologist, 2011, 16, 82-86.	3.7	34
24	Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma. Oncologist, 2012, 17, 856-862.	3.7	32
25	Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials. Oncology, 2015, 88, 345-352.	1.9	31
26	Neutrophilâ€“toâ€“lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Anticancer Research, 2019, 39, 5675-5682.	1.1	30
27	Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma. Oncology, 2012, 82, 59-66.	1.9	29
28	Characteristics and Risk Factors of Oxaliplatin-related Hypersensitivity Reactions. Journal of the Formosan Medical Association, 2010, 109, 362-368.	1.7	28
29	Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 80-88.	1.1	27
30	Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. Japanese Journal of Clinical Oncology, 2010, 40, 286-293.	1.3	27
31	Survival of Patients with Small Cell Lung Carcinoma in Taiwan. Oncology, 2012, 82, 19-24.	1.9	25
32	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1336-1341.	2.8	25
33	Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan. Journal of Pain and Symptom Management, 2017, 54, 55-65.e1.	1.2	25
34	Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Research, 2008, 28, 3115-7.	1.1	25
35	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. British Journal of Cancer, 2012, 107, 1672-1677.	6.4	24
36	Type 2 Diabetes Mellitus Is Associated With Increased Mortality in Chinese Patients Receiving Curative Surgery for Colon Cancer. Oncologist, 2014, 19, 951-958.	3.7	24

#	Article	IF	Citations
37	Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. Journal of the Formosan Medical Association, 2021, 120, 559-566.	1.7	24
38	Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size. PLoS ONE, 2013, 8, e80276.	2.5	23
39	Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. European Journal of Cancer, 2013, 49, 106-114.	2.8	20
40	High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy. Oncology, 2011, 81, 98-103.	1.9	19
41	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemotherapy and Pharmacology, 2017, 79, 421-429.	2.3	19
42	National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients. Oncologist, 2017, 22, 843-849.	3.7	19
43	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. Journal of Hepatocellular Carcinoma, 2014, 1, 85.	3.7	17
44	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	3.7	17
45	Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. Anticancer Research, 2017, 37, 2593-2599.	1.1	17
46	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed antiâ€angiogenic therapy. Liver International, 2013, 33, 1413-1419.	3.9	15
47	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 12880.	4.1	15
48	Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma. Clinical Lung Cancer, 2015, 16, 137-143.	2.6	14
49	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist, 2020, 25, e1280-e1285.	3.7	14
50	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer, 2022, 22, 55.	2.6	14
51	Survival Following Surgery with or without Adjuvant Chemotherapy for Stage Iâ€“IIIA Non-Small Cell Lung Cancer: An East Asian Population-Based Study. Oncologist, 2012, 17, 1294-1302.	3.7	13
52	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma. Cancer, 2013, 119, 1210-1216.	4.1	13
53	The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. Oncologist, 2015, 20, 1051-1057.	3.7	13
54	Right or left? Side selection for a totally implantable vascular access device: a randomised observational study. British Journal of Cancer, 2017, 117, 932-937.	6.4	13

#	Article	IF	Citations
55	Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers, 2019, 11, 1433.	3.7	13
56	A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life. Supportive Care in Cancer, 2019, 27, 2857-2867.	2.2	13
57	Lenalidomide as secondâ€line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. Alimentary Pharmacology and Therapeutics, 2017, 46, 722-730.	3.7	12
58	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. Supportive Care in Cancer, 2017, 25, 533-539.	2.2	12
59	Young patients with colorectal cancer have increased risk of second primary cancers. Japanese Journal of Clinical Oncology, 2015, 45, 1029-1035.	1.3	11
60	Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells. Oncotarget, 2017, 8, 86681-86692.	1.8	11
61	Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. Anticancer Research, 2011, 31, 4007-11.	1.1	11
62	Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma. Anticancer Research, 2012, 32, 4865-70.	1.1	11
63	Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. British Journal of Cancer, 2022, 126, 1806-1814.	6.4	11
64	Satisfaction with pain management and impact of pain on quality of life in cancer patients. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e91-e98.	1.1	10
65	Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy. Oncologist, 2012, 17, 970-977.	3.7	9
66	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. Journal of Cancer, 2016, 7, 1515-1523.	2.5	9
67	Key opioid prescription concerns in cancer patients: A nationwide study. Acta Anaesthesiologica Taiwanica, 2016, 54, 51-56.	1.0	9
68	Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. Discovery Medicine, 2010, 9, 538-45.	0.5	9
69	Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma. Oral Oncology, 2010, 46, 694-697.	1.5	8
70	Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study. Supportive Care in Cancer, 2019, 27, 1663-1672.	2.2	8
71	It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. Journal of the Formosan Medical Association, 2021, 120, 1-4.	1.7	8
72	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 144-150.	1.4	8

#	Article	IF	Citations
73	An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2021, 26, 422-426.	3.7	8
74	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy. Anticancer Research, 2014, 34, 1047-52.	1.1	8
75	The Germline BIM Deletion Polymorphism Is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncology, 2013, 85, 312-316.	1.9	6
76	Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. Diagnostics, 2021, 11, 1340.	2.6	6
77	Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study. Anticancer Research, 2017, 37, 7095-7104.	1.1	6
78	Modern Prospection for Hepatic Arterial Infusion Chemotherapy in Malignancies with Liver Metastases. International Journal of Hepatology, 2013, 2013, 1-11.	1.1	5
79	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621.	3.0	5
80	Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma. Cells, 2021, 10, 1698.	4.1	5
81	Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan. The Lancet Regional Health - Western Pacific, 2021, 16, 100255.	2.9	5
82	Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases. Journal of the Formosan Medical Association, 2014, 113, 577-578.	1.7	4
83	Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure. Liver Cancer, 2018, 7, 205-208.	7.7	4
84	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. Journal of the Formosan Medical Association, 2020, 120, 1581-1590.	1.7	4
85	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Anticancer Research, 2018, 38, 4805-4812.	1.1	3
86	Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management. Journal of Opioid Management, 2019, 15, 147-158.	0.5	3
87	Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. Cancers, 2021, 13, 4962.	3.7	3
88	Solving the deficit of cancer pain management skills by education programs. Supportive Care in Cancer, 2021, 29, 1843-1848.	2.2	2
89	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. Cancers, 2021, 13, 5142.	3.7	2
90	Reply to letter to the editor: Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinoma. Journal of the Formosan Medical Association, 2021, 120, 781-782.	1.7	1

#	Article	IF	Citations
91	Predicting prognosis of patients with advanced hepatocellular carcinoma treated with antiangiogenic therapy using the CUPI and CLIP staging systems.. Journal of Clinical Oncology, 2011, 29, e14669-e14669.	1.6	1
92	Effect of national policy changes on hospice utilization and the invasiveness of end-of-life care in cancer patients.. Journal of Clinical Oncology, 2016, 34, 10008-10008.	1.6	1
93	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, e15656-e15656.	1.6	1
94	Abstract 2052: WNT/beta-catenin signaling inhibitors improve the anti-proliferative effect of sorafenib against hepatocellular carcinoma (HCC) cells.. , 2013, , .		1
95	Abstract 17: Hepatitis C virus (HCV) core protein potentiates proangiogenic activity of hepatocellular carcinoma (HCC) cells. Cancer Research, 2014, 74, 17-17.	0.9	1
96	Abstract 80: Pooled shRNA screening using mouse xenografts of human hepatocellular carcinoma cells identifies CDK5 as a potential mechanism mediating sorafenib resistance. , 2017, , .		1
97	Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment. Anticancer Research, 2009, 29, 1665-7.	1.1	1
98	ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis. Oncology, 2022, 100, 419-428.	1.9	1
99	Influence of age on opioid prescription of patients with advanced lung cancer. Annals of Oncology, 2016, 27, vi457.	1.2	0
100	P3.07-009 Use of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: The Real-World Clinical Practice in Taiwan. Journal of Thoracic Oncology, 2017, 12, S1435-S1436.	1.1	0
101	Abstract 4128: Serum insulin-like growth factor (IGF)-1 levels predict treatment efficacy of anti-angiogenic therapy for patients with advanced hepatocellular carcinoma (HCC). , 2011, , .		0
102	Abstract 4584: Î²-catenin (CTNNB1) and BRAF mutations in advanced hepatocellular carcinoma. , 2012, , .		0
103	Abstract 1904: Transforming growth factor-beta mediated epithelial to mesenchymal transition contributes toin vivoresistance to sorafenib in hepatocellular carcinoma. , 2012, , .		0
104	Unique histopathologic features of brain metastases from hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, 169-169.	1.6	0
105	Association of diabetes mellitus with increased mortality in patients receiving curative surgery for colon cancer.. Journal of Clinical Oncology, 2013, 31, 399-399.	1.6	0
106	Abstract 3547: The BIM deletion polymorphism not associated with treatment efficacy of sorafenib for advanced hepatocellular carcinoma.. , 2013, , .		0
107	Clinical Activity of Metronomic Chemotherapy in Liver Cancers. , 2014, , 189-202.		0
108	Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).. Journal of Clinical Oncology, 2014, 32, 4100-4100.	1.6	0

#	Article	IF	Citations
109	Risk of second primary malignancies in young patients with colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e14533-e14533.	1.6	0
110	The impact of diabetes mellitus on early cervical cancer in Î¹sia: A population-based cohort study.. Journal of Clinical Oncology, 2014, 32, e16501-e16501.	1.6	0
111	Abstract 2865: High serum transforming growth factor Î²1 levels associated with poor survivals in patients with advanced hepatocellular carcinoma. , 2014, , .		0
112	Tumor c-Met expression and prognosis of advanced hepatocellular carcinoma patients treated with sorafenib.. Journal of Clinical Oncology, 2015, 33, 317-317.	1.6	0
113	Abstract 5421: HER3 inhibition has little efficacy on hepatocellular carcinoma cell lines. , 2015, , .		0
114	Abstract 5336: Improved antitumor effect of combining WNT/beta-catenin inhibition with sorafenib in hepatocellular carcinoma. , 2015, , .		0
115	Abstract 2831: Composite cyclin dependent kinase inhibition shows potent activity against hepatocellular carcinoma. , 2016, , .		0
116	Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.. Journal of Clinical Oncology, 2017, 35, 624-624.	1.6	0
117	Abstract 4728: Plasma interleukin-6 level predicts prognosis of patients who received sorafenib for advanced hepatocellular carcinoma. , 2017, , .		0
118	Abstract 1636: Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment. , 2017, , .		0
119	Abstract 3627: Organ-specific differential responses to immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma. , 2018, , .		0
120	Abstract 4964: Associations between hepatitis etiology and immune cell infiltration in or around hepatocellular carcinoma. , 2019, , .		0
121	Abstract 1590: High ICOS/FOXP3 Tregs content in the tumor microenvironment is associated with poorer survival in patients with hepatocellular carcinoma. , 2020, , .		0
122	Abstract 4964: Associations between hepatitis etiology and immune cell infiltration in or around hepatocellular carcinoma. , 2019, , .		0